Japan-based startup Toregem BioPharma has raised approximately $5.3 million (JPY 850 million) in Pre-Series C financing round of an allocation of J-KISS- type stock acquisition rights to a new investor and also a third-party allotment of new shares with subscribing companies including JIC Venture Growth Investments (VGI)..

日本初创企业Toregem BioPharma完成了约530万美元（约合8.5亿日元）的C轮前融资。本轮融资包括向新投资者配售J-KISS型新股预约权，以及向JIC Venture Growth Investments (VGI)等认购方进行第三方新股定向增发。

Through this funding, Toregem’s cumulative equity financing has reached approximately $16 million (JPY 2.6 billion), and its cumulative funding, including grants and subsidies, has exceeded $29 million (JPY 4.6 billion).

通过此次融资，Toregem的累计股权融资额已达约1600万美元（26亿日元），包含补助金和补贴在内的累计融资总额已超过2900万美元（46亿日元）。

With this Pre-Series C funding, Toregem will conduct Phase II clinical trials of TRG035, a humanised anti-USAG-1 antibody, in Japan, prepare for future clinical development in the United States, and further accelerate the clinical development.

凭借此次C轮前融资，Toregem将在日本开展TRG035（一种人源化抗USAG-1抗体）的II期临床试验，为未来在美国的临床开发做准备，并进一步加速临床开发进程。

TRG035 is expected to offer a new radical therapeutic approach for patients who currently have limited treatment options with dentures or implants, and the startup sets its goal to obtain Japanese approval for launch as a new treatment.

TRG035有望为目前治疗选择仅限于假牙或种植牙的患者提供一种全新的根本性治疗方法，该初创公司旨在获得日本批准，以新疗法身份上市。